Insulin Degludec, Generasi Baru Insulin Analog Kerja Sangat Panjang untuk Terapi Diabetes Melitus Tipe 1
DOI:
https://doi.org/10.55175/cdk.v47i7.601Kata Kunci:
DM tipe 1, insulin basal, insulin degludecAbstrak
Diabetes melitus tipe 1 adalah kelainan sistemik akibat gangguan metabolisme glukosa yang ditandai hiperglikemia kronik; merupakan jenis DM yang paling banyak pada anak. Insulin Degludec merupakan generasi baru insulin basal kerja sangat panjang dengan kelebihan waktu paruh panjang dan tanpa puncak, dapat digunakan untuk DM tipe 1 pada anak.
Type 1 diabetes mellitus is a systemic disorder due to a disturbance in glucose metabolism characterized by chronic hyperglycemia; it is the most common type in children. Insulin Degludec is a new generation of ultra long-acting basal insulin with long half-life and without peak, can be used for type 1 DM in children.
Unduhan
Referensi
International Society for Pediatric and Adolescent Diabetes. ISPAD Clinical Practice Consensus Guidelines; 2018.
Ikatan Dokter Anak Indonesia. Konsensus nasional pengelolaan diabetes mellitus tipe 1; 2015
Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014;53(9):787–800
Thalange N, Biester T, Danne T. Clinical use of degludec in children and adolescents with type 1 diabetes: A narrative review with fictionalized case reports. Diabetes Ther. 2019;10(4):1219–37
Zhang XW, Zhang XL, Xu B, Kang LN. Comparative safety and eficacy of insulin degludec with insulin glargine in type 2 and type 1 diabetes: A meta-analysis of randomized controlled trials. Acta Diabet. 2017;45:28–45
Biester T, Blaesig S, Remus K, Aschemeier B, Kordonouri O, Granhall C, Søndergaard F, et al. Insulin degludec’s ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes. Pediatric Diabetes 2014;15:27–33
Thalange N, Deeb L, Iotova V, Kawamura T, Klingensmith G, Philotheou A, et al. Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2015;16:164–76
Kaku K, Eid MA. Safety, efficacy, and early clinical experience of insulin degludec in Japanese people with diabetes mellitus: A first-year report from Japan. J Diabetes Investig. 2015;6:610-19
Fernanda OL, Keitty RC, Ana CM, Figueiredo G, Silva EN, Pereira MG. Long-acting insulin analogues for type 1 diabetes: An overview of systematic reviews and metaanalysis of randomized controlled trials. PloS ONE. 2017;13(4):e0194801
Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, dan Haahr H. Insulin degludec: Four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14:859–64
Davies M, Sasaki T, Gross JL, Bantwal G, Ono Y, Nishida T, Tojjar D, et al. Comparison of insulin degludec with insulin detemir in type 1 diabetes: A 1-year treat-totarget trial. Diabetes Obes Metab. 2016;18:96–99
Heise T, Nørskov M, Nosek L, Kaplan K. Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes. Diabetes Obes Metab. 2017;19:1032–9.
Thalange N, Deeb L, Klingensmith G, Franco DR, Bardtrum L, Tutkunkardas D, Danne T. The rate of hyperglycemia and ketosis with insulin degludec based treatment compared with insulin detemir in pediatric patients with type 1 diabetes: An analysis of data from two randomized trials. Pediatric Diabetes. 2019;20:314–20
Thalange N, Gundgaard J, Parekh W, Tutkunkardas D. Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UKBMJ Open Diab Res Care 2019;7:e000664
Tentolouris A, Eleftheriadou I, Tentolouris N. Insulin degludec U100 is associated with lower risk for severe and symptomatic hypoglycemia as compared with insulin glargine U100 in subjects with type 1 diabetes. Ann Transl Med. 2018;6(3):63
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2020 https://creativecommons.org/licenses/by-nc/4.0/
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
